November 06, 2024

Find out what happens to a woman and her child’s body if sugar consumption is restricted in the first 1000 days after conception

The mother’s diet may influence a child’s lifelong health, according to a new study. Published in the journal Science, it was found that reducing sugar in the first 1,000 days after conception, throughout gestation, and up to the age of 2 of the child may help cut the risk of chronic illnesses, especially diabetes, in adulthood. The researchers indicated that the risk of type 2 diabetes was reduced by about 35 per cent while high blood pressure risk was cut by roughly 20 per cent. “They also found a delay in disease onset of four and two years, respectively,” it read.

The study authors looked at data from before and after the end of the United Kingdom’s World War II-era sugar rationing in September 1953 when the UK began rationing to allow “fair shares” of food for the country during the wartime shortage. According to the Imperial War Museums, access to foods like sugar, fats, bacon, meat, and cheese was limited. However, when the rationing of sugar and sweets ended in September 1953, sugar consumption doubled immediately.

Why is sugar a concern?

Dr Rajiv Kovil, head of diabetology at Zandra Healthcare and co-founder of Rang De Neela Initiative, said obesity drives the epidemic of diabetes, cancer, and heart disease. “Sugar cravings are often rooted in both biology and psychology. Biologically, sugar stimulates dopamine release, giving a “feel-good” sensation. Over time, this can become habit-forming, leading to cravings.

Here’s what happens when you forgo sugar (Source: Freepik)

“I strongly believe sugar is the biggest addiction in this world. During periods like World War II, many countries rationed sugar due to limited availability. People adapted by using substitutes or simply consuming less. These rationing periods highlighted how reducing sugar availability influenced dietary habits, and obesity rates were much lower. Post-rationing, however, sugar intake surged, correlating with an increase in obesity rates,” added Dr Kovil.

Our forefathers used to get food once in a while. “Hence, our genes store fat in the liver, muscles, etc, to make it available when food is unavailable. This is called the thrifty gene hypothesis,” said Dr Kovil.

This hypothesis suggests that humans evolved to efficiently store energy in the form of fat during food abundance. “In ancient times, people faced frequent food scarcity, so individuals with a ‘thrifty’ genotype who stored fat more effectively were more likely to survive during famines. This adaption in our genes becomes a liability and maladaption today when we have abundant food,” said Dr Kovil.

Today, however, this once-beneficial genetic trait can lead to an increased risk of obesity and metabolic disorders. “In a world where high-calorie, sugar-rich foods are easily accessible, the ‘thrifty’ genotype may contribute to weight gain and obesity, as these individuals are predisposed to store excess energy,” said Dr Kovil.

What are the effects of sugar on maternal and child health?

Dr Poonam Sidana, director of neonatology and paediatrics at CK Birla Hospital, Delhi, noted that the first 1000 days of life, which include the 40 weeks of pregnancy (approximately 280 days) and the first two years of life (about 730 days), are crucial for a child’s development. “This period is essential for optimal nutrition, and recent research has refocused attention on the impact of high sugar intake during pregnancy,” said Dr Sidana.

The findings reinforce the idea that excessive sugar intake during pregnancy, particularly among mothers who are overweight or consume more sugar than recommended, can have lasting effects on both maternal and child health. “Public health experts have long recognised the importance of improved nutrition in the first 1000 days of life, linking maternal health and nutrition with long-term cognitive development, risk of chronic diseases, and lifestyle issues in the child’s future. If a mother is overweight before or during pregnancy, there is a heightened risk of gestational diabetes, hypertension, and obesity in the newborn. Overweight infants are more likely to experience complications, such as the need for cesarean or instrumental deliveries,” said Dr Sidana.

Furthermore, if a mother consumes high-sugar, processed foods, she may be “depriving herself and her baby of other essential nutrients, impacting both their health.” “Studies indicate that babies exposed to high sugar content in utero are at increased risk of obesity, allergies, and chronic conditions like diabetes and hypertension later in life,” said Dr Sidana.

The importance of maternal health extends beyond pregnancy. A “life cycle approach” to women’s health is essential, which includes promoting a healthy diet, ensuring vaccination,

and conducting pre-pregnancy check-ups to identify and address any issues early. “During pregnancy, guidance on healthy eating, with a focus on fresh foods, whole grains, and regular exercise, can significantly improve outcomes,” said Dr Sidana.

Breastfeeding, particularly exclusive breastfeeding for the first six months, is also essential for a child’s immunity, neurodevelopment, and long-term health. “Research shows that mothers with healthier lifestyles during pregnancy are more likely to breastfeed. Once the child begins semi-solids, the focus should remain on fresh, home-cooked food, with natural sweeteners like fruits and nuts rather than processed sugars,” said Dr Sidana, emphasising that it helps support healthy habits in young women, mothers, and infants.

https://indianexpress.com/article/lifestyle/health/what-happens-woman-child-sugar-restricted-first-1000-days-after-conception-pregnancy-diabetes-risk-benefits-experts-9654242/

Can Ozempic and Wegovy help reduce knee osteoarthritis-related pain?

A new trial finds that GLP-1 agonists may help reduce knee osteoarthritis-related pain.

The use of GLP-1 medications such as semaglutide — more widely known under the brand names of Ozempic and Wegovy — have greatly increased over the last few years.

There has also been an increase in research examining other benefits these types of drugs might offer aside from type 2 diabetes management and weight loss.

Recent results from a phase 3 clinical trial show that semaglutide may help reduce knee osteoarthritis-related pain in people with obesity.

The use of glucagon-like peptide-1 (GLP-1) medications such as Wegovy and Ozempic has greatly increased over the last few years.

While these drugs are mainly used to help control type 2 diabetes and boost weight loss, over the last few years, there has been a lot of research surrounding GLP-1 medications, such as semaglutideTrusted Source, and how they provide additional benefits.

For example, recent studies report that GLP-1 drugs may have neuroprotective benefitsTrusted Source, lower Alzheimer’s diseaseTrusted Source risk, and offer protection against cardiovascular disease.

Now, new clinical trial results recently published in The New England Journal of Medicine show that semaglutide may also help reduce knee osteoarthritis-related pain in people with obesity.

Semaglutide reduces pain scores for knee osteoarthritis

This new study featured the results from the STEP 9 phase 3 clinical trial conducted by healthcare company Novo Nordisk aimed at evaluating the efficacy of semaglutide versus placebo as an additional to lifestyle modifications — such as eating a reduced-calorie diet

and exercising — in lowering weight and knee osteoarthritis-related pain in patients with obesity.

Researchers recruited 407 participants with an average age of 56 and body-mass index (BMI) of 40.3 for the study, who received either a 2.4 mg dose of semaglutide once a week or a placebo for 68 weeks.

At 68 weeks, researchers found that participants taking semaglutide experienced a mean decline in their body weight by 13.7%, compared to a 3.2% decrease in those taking the placebo.

Researchers also evaluated study participants’ Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores during this study. WOMAC is a patient-reported questionnaire that helps rank pain on a scale of zero to 100, with higher numbers indicating more pain.

Scientists discovered that those taking semaglutide experienced a mean decrease in their WOMAC pain score of 41.7 points from 70.9 at the start of the study, compared to those taking the placebo whose WOMAC scores only decreased by 27.5 points.

“Obesity-related knee osteoarthritis is a progressive condition that can lead to pain and stiffness of the knee and impair critical daily functions such as walking or moving around,” Henning Bliddal, MD, MSci, clinical professor in the Department of Clinical Medicine and director of the Parker Institute at Copenhagen University Hospital in Denmark and lead author of this study says in a press release.

“The risk of developing the condition is more than four times higher in people with obesity. Weight reduction along with physical activity is often a recommended approach to managing painful symptoms, but adherence can be challenging. There is a significant need for non-surgical and sustainable treatment options for those living with obesity-related osteoarthritis. The STEP 9 trial aimed to provide rigorous evidence as to how semaglutide may help these people,” Bliddal says.

Too early to prescribe Ozempic for osteoarthritis

After reviewing this study, Mir Ali, MD, a board certified general surgeon, bariatric surgeon and medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA, told Medical News Today that its findings were in line with what doctors have seen with any kind of weight loss.

“As a patient loses weight, all of their medical conditions improve, including pain from osteoarthritis. They’re taking pressure off of those joints, so it improves their discomfort and we see that with our surgical weight loss patients as well.” — Mir Ali, MD

“That’s a big factor for a lot of people because the more discomfort they have in their joints, the less active they are. And the less active they are, the easier it is to gain weight. So if you can find ways to reduce pain and inflammation in the joints to allow them to be more active,

then they can be more proactive about exercise and other ways to improve their health and lose weight,” Ali explained.

Ali said he would be interested in seeing if researchers can eventually show that semaglutide improves inflammation independent of weight loss.

“That would be a tough study to design, but that would be helpful to show that there’s some additional effect, not just the weight loss,” he added.

Semaglutide may have anti-inflammatory effects

MNT also spoke with Bert Mandelbaum, MD, sports medicine specialist and orthopedic surgeon at Cedars-Sinai Kerlan-Jobe Institute and Co-Director of the Regenerative Orthobiologic Center at Cedars-Sinai Medical Center in Los Angeles, about this study.

“Certainly we have always known that obesity is a risk factor for not only the onset of osteoarthritis, but the progression of it — there is no question about that. When you have a study like this that shows that there’s two things that are happening at one time. One is that obviously their patients are losing weight, so there’s a physical and mechanical aspect, but also there’s something about semaglutide that also has an anti-inflammatory (effect).” — Bert Mandelbaum, MD

“It’s not proven in this study, but there have been other studies that show that (semaglutide) reduces cardiovascular risks. And the mechanisms of that are that it is functionally an anti-inflammatory as well. It has another effect, creating a decreased inflammation that affects blood vessels in and of themselves, as well as other catabolic mediators such as the interleukinsTrusted Source and TNF (tumor necrosis factor), and other metalloproteases seem to be inhibited as part of its inhibitory inflammatory effect,” Mandelbaum said.

Mandelbaum said doctors are looking for help in reducing pain from osteoarthritis, whether it’s related to obesity or not.

“Obesity is just a negative factor that worsens the challenge for us. We’re trying to reduce the amount of what we call catabolism and create an anabolic environment for the joints,” he explained.

“I think if researchers have found that we could reduce cardiovascular disease with these medicines, we can reduce the pain from osteoarthritis,” Mandelbaum continued.

“At the end of the day, the orthobiologic family, we have to look at other things that can make a difference, along with taking Wegovy or any of the other GLP-1s. So I think it’s an interesting study, but (it) really portends us to really think about what our next steps are so we can get into more adjuvant approaches, in addition to this, at the same time,” he added.

https://www.medicalnewstoday.com/articles/ozempic-wegovy-obesity-help-reduce-knee-osteoarthritis-pain 

Blood-biomarker tests may aid in early diagnosis of Alzheimer's: Report

While early detection of Alzheimer’s disease is crucial for better outcomes, a report on Wednesday said that blood-based tests are emerging as valuable tools.

The report by GlobalData, a data and analytics company, offers accessible alternatives to PET scans and cerebrospinal fluid (CSF) analysis.

Currently, Alzheimer’s affects over 55 million people globally, and cases are projected to triple by 2050.

Advances in diagnostic methods that can make diagnosis faster, less invasive, and more affordable can help in the timely intervention of the neurodegenerative disease. However, the report said questions remain about their real-world impact on patient outcomes.

Ashley Clarke, Senior Medical Analyst at GlobalData said that blood-based biomarker tests that are cost-effective and efficient in early assessment, have taken a major leap forward in diagnostics with it being used for conditions like heart attacks.

“For Alzheimer’s disease, reliable and accessible testing could lead to earlier detection, giving patients more time to pursue interventions and lifestyle changes,” Clarke said.

According to GlobalData’s Pipeline Products Database, more than 150 in vitro diagnostic tests for Alzheimer’s disease are currently in development. However, the USFDA has yet to grant full approval to blood-based Alzheimer’s tests.

“With high negative predictive values, blood-based tests could serve as reliable screening tools, helping reserve hospital resources for procedures such as PET scans for patients most likely to need them,” Clarke said.

GlobalData reports that at least five pipeline devices are now in the regulatory approval process across the US and Europe, yet ethical and regulatory challenges persist.

These tests raise concerns about overdiagnosis, exposure of sensitive health data, and the potential for insurers to adjust premiums based on test outcomes.

Predictive testing also introduces ethical considerations around informed consent, and potential psychological impacts for patients learning their risks in a disease still lacking a cure, the report said.

https://www.newkerala.com/news/2024/69734.htm

Consuming high levels of omega-3, omega-6 may keep cancer at bay

Omega-3 and omega-6 fatty acids are "healthy fats" and essential for human health.

A higher consumption of omega-3 and omega-6 fatty acids may help ward off a variety of cancers, finds a study of more than 2,50,000 people on Tuesday.  Cancer has become a global health concern, especially with increasing early onset.

Omega-3 and omega-6 fatty acids are "healthy fats" and essential for human health. These are important to the cells and are known to reduce bad cholesterol levels, keep the brain healthy and boost mental health. Higher levels of omega-3s showed protection against colon, stomach and lung cancer, according to the study, published in the International Journal of Cancer.

On the other hand, high omega-6 levels protect against brain, malignant melanoma, bladder and 14 different cancers. "Higher omega-3 and omega-6 levels were associated with lower rates of cancer," said lead author Yuchen Zhang, a doctoral student at the University of Georgia's College of Public Health.

Zhang noted that with the significant rise in cancers worldwide, the study “suggests that the average person should focus on getting more of these fatty acids in their diets.”

The researchers analysed data from more than 2,50,000 people, of which about 30,000 developed some form of cancer in the 10 years of follow-up.

Omega-3 and omega-6 are present in fatty fish, nuts and even some plant oils. However, as diets may not provide the recommended amounts, people often turn to fish oil supplements — one of the most popular dietary pills on the market. However, it may not be suitable for all, said the researchers.

 The study showed that elevated omega-3 levels raised a slightly higher risk of prostate cancer in men. However, the study found no such associations in women. Instead, it found women and young people to have “stronger beneficial effects of omega-6”.

https://www.tribuneindia.com/news/health/consuming-high-levels-of-omega-3-omega-6-may-keep-cancer-at-bay/